Several authors'-6 have described increased levels of growth hormone in peripheral plasma in patients with chronic liver disease. These studies have indicated both an increase in fasting values and lack of suppression or even a paradoxical rise in plasma levels after glucose loading.
The cause of the raised growth hormone levels in patients with liver disease remains uncertain and has been attributed to impaired degradation7 or increased secretion.8
Although the implications of the raised growth hormone levels in the pathogenesis of the glucose intolerance which develops in such patients has been discussed, no firm conclusions can be drawn in regard to its role in this situation. Only one study3 has attempted to correlate glucose intolerance in individual patients with abnormality in growth hormone levels. These authors showed that in a group of patients with chronic hepatic cirrhosis those with impaired glucose tolerance showed higher growth hormone levels during the GTT than those cirrhotic patients with normal glucose tolerance. They concluded, therefore, that high growth *Address for correspondence: Dr W J Riley, Department of Biochemistry, Royal Perth Hospital, GPO Box X2213, Perth, Western Australia, 6001.
Reprints will not be available from the authors Recei\ed for publication 29 October 1980 hormone levels may be responsible for the high incidence of abnormal glucose tolerance in hepatic cirrhosis.
The present work describes a similar study in a group of patients with chronic liver disease in whom we investigated the correlation between the degree of glucose tolerance and the level of circulating growth hormone.
Methods

PATIENTS
Plasma glucose, insulin, and growth hormone levels were estimated during an oral glucose tolerance test in 30 patients with chronic liver disease. These patients were selected on the basis of the usual clinical features of hepatic cirrhosis: enlarged liver and spleen, palmar erythema, spider naevi, and signs of portal hypertension, together with the laboratory findings of hyperbilirubinaemia, hypoalbuminaemia, hypergammaglobulinaemia, and a rise in transaminases. In the majority the diagnosis was confirmed by liver biopsy. Sixteen patients had alcoholic cirrhosis, eight had active chronic hepatitis, five had cryptogenic cirrhosis, and one had biliary cirrhosis.
Patients were classified as 'diabetic', 'impaired glucose tolerance ', or 'normal' with respect to a 50 g oral GTT according to the criteria shown in Table 1 . Table 2 . Although, for convenience, the terms normal and abnormal have been used, it makes no difference to our subsequent argument if the two groups are regarded simply as having different degrees of impairment.
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Comparison of the insulin response in those patients with normal or abnormal growth hormone response is shown in Fig. 4 . Again the two groups show similar circulating insulin levels at all sampling points. The data do not provide any evidence to suggest that increased growth hormone levels are associated with increased insulin output to maintain similar glucose levels in the two groups. 
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Discussion
The occurrence of impaired glucose tolerance10 and a rise in peripheral growth hormone levels in chronic liver disease1-6 have been well described. The findings of this study in this respect are in agreement with published findings. Thus, approximately 20-50 % of cirrhotic patients are expected to show some degree of impairment of glucose tolerance and in our group 14 out of 30 were so classified. Similarly, we found that a very high proportion of our patients showed a paradoxical lack of suppression or even a rise in growth hormone levels after a 50 g glucose challenge. Sixteen of our 30 patients were classified as abnormal in this respect. In addition, four patients had moderately increased fasting levels of growth hormone but showed normal suppression after glucose.
Although the abnormalities in glucose tolerance and growth hormone levels are well documented, the relationship between the two is not clear. Samaan and co-workers3 found that abnormalities in growth hormone were more marked in those patients with hepatic cirrhosis who had impaired glucose tolerance than in those with normal glucose tolerance. They suggested, therefore, that the high levels of growth hormone and their lack of suppression with hyperglycaemia may play a role in producing an insensitivity to insulin in patients with liver disease.
Our findings are in disagreement with this, in that no statistical significance can be found with respect to degree of growth hormone abnormality and degree of glucose intolerance. No satisfactory explanation is readily available to explain this difference in findings, but, of course, it is possible that our patient population was in some way different from that of Samaan and his colleagues. It is also possible that it may be due to the very wide differences in growth hormone response seen in individual patients in our series. In an attempt to overcome this, patients were classified according to whether they had a normal or abnormal growth hormone response to glucose. As demonstrated in Fig. 5 no difference in glucose tolerance could be discerned in the two groups; and it therefore appears doubtful as to whether growth hormone plays a significant role in producing abnormalities in the handling of glucose in these patients.
If the raised growth hormone levels were responsible for promoting hyperinsulinism and insulin resistance in patients with liver disease one might expect to find differences in the insulin response to glucose in the group with abnormal growth hormone response as compared with that with normal growth hormone. That this is not so is seen in Fig. 4 again we have failed to produce any evidence that growth hormone plays a role in this regard. Previous studies310 have, in fact, indicated that hyperinsulinism is a common finding in liver disease. Moreover, the studies of Samaan and co-workers have indicated that the exaggerated insulin response to glucose is associated with those patients exhibiting a normal tolerance for glucose. Where there is impaired glucose tolerance the insulin response is lessened. These findings are confirmed by the present work, which indicates that a smaller increment of insulin over the fasting level occurs in these patients as compared with those with normal glucose tolerance.
In conclusion, the group of patients we have studied appear to be similar to those observed by other workers both in respect to the number exhibiting impaired glucose tolerance, in the nature of their insulin response to glucose, and in respect to abnormal circulating growth hormone levels. We have not, however, been able to demonstrate any relationship between the latter and the degree of impairment of glucose tolerance or the nature of the insulin response. It would seem unlikely from our results that growth hormone plays a major role in the development of impaired glucose tolerance. Other workers have commented on the possibility that oestrogens may inhibit peripheral effects of growth hormone in these patients, as they do not develop clinical features such as those seen in acromegaly. It is possible that the effects of growth hormone on carbohydrate metabolism are also inhibited by some unidentified factor. 304 group.bmj.com on October 14, 2017 -Published by http://gut.bmj.com/ Downloaded from The reduced insulin secretion in patients with impaired glucose tolerance would suggest that this is related to impaired beta cell function rather than to insulin resistance. There are a number of ways in which the association may occur-for example, patients with alcoholic liver disease may well have an associated alcoholic pancreatitis and it has been shown that both active chronic hepatitis11 and juvenile onset diabetes'2 13 share an association with the histocompatibility antigen HLA B8.
Additional investigation is required to clarify the cause of impaired glucose tolerance in patients with chronic liver disease but it seems likely that the association arises through more than one mechanism.
